68Ga-PSMA-PET/CT整合入前列腺癌放疗计划
该回顾性研究分析191例接受根治性调强放疗的前列腺癌患者,比较常规分期(胸腹部CT+骨显像)与68Ga-PSMA-PET/CT二次分期对风险分组和放疗决策的影响。结果显示26例(13.6%)风险分组改变,30例(15.7%)升期,22例(11.5%)降期,26例(13.6%)淋巴结分期改变,13例(6.8%)追加盆腔淋巴引流区照射,6例(3.2%)追加转移灶照射,4例(2.1%)因发现实质或远处转移中止放疗。
要点
- 68Ga-PSMA-PET/CT使13.6%患者风险分组改变、15.7%升期。
- 13.6%患者淋巴结分期改变,8.9%患者转移数增加。
- 6.8%追加盆腔淋巴照射,3.2%追加转移灶照射,2.1%中止放疗。
核心结论
- 68Ga-PSMA-PET/CT引起相当比例患者的分期、风险分组和放疗野安排迁移,尤其在高危患者中,且独立于GS和基线PSA值。
- 68Ga-PSMA-PET/CT对前列腺癌患者的放疗决策有较大影响。
研究设计与样本
- 回顾性分析191例接受根治性调强放疗的前列腺癌患者临床数据。
- 所有患者初诊分期采用胸腹部CT和骨显像,二次分期采用68Ga-PSMA-PET/CT。
- 评估两种分期对放疗决策及靶区体积改变的影响。
主要发现
- 68Ga-PSMA-PET/CT分期后26例(13.6%)风险分组改变,其中16例(8.4%)风险分组升高、10例(5.2%)降低。
- 降期22例(11.5%),升期30例(15.7%)。
- 26例(13.6%)淋巴结分期改变。
- 68Ga-PSMA-PET/CT扫描后转移患者增至17例(8.9%),其中4例从寡转移转为多转移。
- 13例(6.8%)追加盆腔淋巴引流区照射,6例(3.2%)追加转移灶照射,4例(2.1%)因实质或远处转移中止放疗。
临床怎么用
- 在前列腺癌根治性放疗前可考虑行68Ga-PSMA-PET/CT二次分期以优化风险分组和靶区设计。
- 对高危患者尤其应关注68Ga-PSMA-PET/CT对分期和放疗野安排的影响。
局限性
- 本研究为回顾性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: To assess the role of Gallium-labeled-prostate-specific membrane antigen PET/CT (Ga-PSMA-PET/CT) in risk group definition and radiotherapy planning in the initially planned definitive radiotherapy (RT) for prostate cancer patients. METHODS: The clinical data of 191 prostate cancer patients treated with definitive intensity-modulated RT were retrospectively analyzed. All patients were initially staged with thoracoabdominal CT and bone scintigraphy, and the second staging was performed using Ga-PSMA-PET/CT. Both stages were evaluated for the decision making of RT and any change in RT target volumes. RESULTS: After staging with Ga-PSMA-PET/CT, 26 patients (13.6%) had risk group changes, 16 patients (8.4%) had an increase in risk group, and 10 patients (5.2%) had a decrease in risk group. Down-staging occurred in 22 patients (11.5%), and upstaging was observed in 30 patients (15.7%). A total of 26 patients (13.6%) had nodal stage changes. After the Ga-PSMA-PET/CT scans, the number of metastatic patient increased to 17 (8.9%), with 4 of them moving from oligo- to polymetastatic disease. An additional irradiation of pelvic lymphatics and metastatic site was performed in 13 patients (6.8%) and 6 patients (3.2%), respectively. The RT was aborted in 4 patients (2.1%) because of parenchymal or distant site metastasis observed in the Ga-PSMA-PET/CT. CONCLUSIONS: We found that Ga-PSMA-PET/CT causes considerable migration in stage, risk group, and RT field arrangements, especially in high-risk patients regardless of the GS and baseline prostate-specific antigen values alone. Ga-PSMA-PET/CT seems to have a great influence on RT decision making in prostate cancer patients.
引用
- Onal C, Torun N, Akyol F, et al. Integration of 68Ga-PSMA-PET/CT in Radiotherapy Planning for Prostate Cancer Patients. Clin Nucl Med. 2019. PMID: 31283600. doi:10.1097/RLU.0000000000002691
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。